KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elevance Health (ELV) Capital Expenditures (2016 - 2025)

Elevance Health (ELV) has disclosed Capital Expenditures for 17 consecutive years, with $293.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 9.01% to $293.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 billion, a 11.15% decrease, with the full-year FY2025 number at $1.1 billion, down 11.15% from a year prior.
  • Capital Expenditures was $293.0 million for Q4 2025 at Elevance Health, down from $360.0 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $360.0 million in Q3 2025 to a low of $196.0 million in Q1 2025.
  • A 5-year average of $295.3 million and a median of $299.5 million in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: rose 24.51% in 2022, then fell 29.75% in 2025.
  • Elevance Health's Capital Expenditures stood at $340.0 million in 2021, then decreased by 12.35% to $298.0 million in 2022, then rose by 9.4% to $326.0 million in 2023, then dropped by 1.23% to $322.0 million in 2024, then decreased by 9.01% to $293.0 million in 2025.
  • Per Business Quant, the three most recent readings for ELV's Capital Expenditures are $293.0 million (Q4 2025), $360.0 million (Q3 2025), and $267.0 million (Q2 2025).